Exicure (XCUR) Return on Sales (2016 - 2024)

Exicure's (XCUR) quarterly Return on Sales came in at 0.19% in Q4 2024, down 142.3% on a QoQ basis from 0.08% in Q3 2024.

Exicure (XCUR) Return on Sales (2016 - 2024) Analysis & Trends

Exicure (XCUR) has 9 years of Return on Sales data on file, last reported at 0.19% in Q4 2024.

Quarterly Return on Sales changed N/A year-over-year to 0.19% in Q4 2024, while the trailing twelve-month figure through Dec 2024 was 0.19% (changed N/A YoY) and the FY2024 annual result came in at 0.19%, changed N/A from the prior year.
Return on Sales slipped to 0.19% in Q4 2024, from 0.08% in the prior quarter.
In the past five years, Return on Sales ranged from a high of 0.07% in Q4 2021 to a low of 1.81% in Q2 2021.
A 5-year average of 0.18% and a median of 0.03% in 2022 frame the typical range for Return on Sales.
Annual changes were most pronounced in 2020 — Return on Sales jumped 234 bps — and 2021, when it plunged 180 bps.
Tracing XCUR's Return on Sales over 5 years: stood at 0.91% in 2020, then surged by 107 bps to 0.07% in 2021, then sank by 87 bps to 0.01% in 2022, then tumbled by 84 bps to 0.0% in 2023, then slumped by 14341 bps to 0.19% in 2024.
The last three Return on Sales figures came in at 0.19% (Q4 2024), 0.08% (Q3 2024), and 0.16% (Q2 2024), per Business Quant data.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	ROS (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	0.00%
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	0.00%
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	0.00%
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	-0.05%
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	0.00%
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	0.00%
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	0.00%
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	0.00%
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	0.00%
10	Exicure	7.27 Mn	7.27 Mn	-	-

Download Data